Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of YR011 in Healthy Participants
NCT07285967Phase 1Not yet recruiting
- Sponsor
- Hangzhou Yirui Pharmaceutical Technology Co., Ltd.
- Start
- Apr 2027
- Primary completion
- Sep 2027
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial comparing YR011 with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events up to 44 days. Planned start Apr 2027; status: not yet recruiting.
02
Drugs
PA032
Beyond the preview
Go deeper on NCT07285967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07285967.